To better understand CHEK2 variants and differences in cancer phenotypes, Ambry’s Carrie Horton, Senior Medical Liaison; Dr. Marcy Richardson, Manager of Clinical Research; Amal Yussuf, Manager of Clinical Data Analytics and Dr. Colin Young, Variant Assessment Scientist, partnered with the Dana-Farber Cancer Institute to publish a study in JAMA Oncology: “Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care: Checking CHEK2.” The study harnessed the power of Ambry’s large clinical dataset to show that most CHEK2 variants have similar cancer risks, with three notable exceptions. These results can help form future medical guidelines with a better understanding of the CHEK2 pathogenic variants.

Read the study here: https://hubs.ly/Q01n10hl0.